Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Blood Cancer Journal|May 13, 2020
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Brian G M Durie, Antje Hoering, Rachael Sexton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple MyelomaSikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, et al.
Blood|September 25, 2024
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysisRahul Banerjee, Rachael Sexton, Andrew J Cowan, et al.
Journal of the Society for Clinical Data Management|June 13, 2025
Automating Data Entry from Electronic Health Record to Electronic Data Capture Using a Trusted Cloud-Based Application in Multisite Cancer Clinical TrialsKeith Goodman, Chris Cook, Dani Weatherbee, et al.
The Lancet. Haematology|December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trialSaad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.
Blood|April 23, 2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myelomaSaad Z Usmani, Jeffrey Sawyer, Adam Rosenthal, et al.
JCI Insight|April 20, 2018
Antigen-mediated regulation in monoclonal gammopathies and myelomaShiny Nair, Joel Sng, Chandra Sekhar Boddupalli, et al.
JAMA|February 14, 2013
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communitiesDouglas R Morgan, Javier Torres, Rachael Sexton, et al.
European Urology Oncology|June 20, 2025
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed TherapyJesus E Juarez Casillas, John Nikitas, Matthew B Rettig, et al.
Pageof 2